The Barcelona Institute for Global Health (ISGlobal) is the fruit of an innovative alliance between the "la Caixa" Foundation, academic institutions and government bodies to contribute to the efforts undertaken by the international community to address the challenges in global health.
ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. The pivotal mechanism of its work model is the transfer of knowledge generated by scientific research to practice, a task undertaken by the institute’s Education and Policy and Global Development departments. Its ultimate goal is to help close the gaps in health disparities between and within different regions of the world.
Main roles in project
Carlota Dobaño is a Research Professor (Vaccinology Module) and head of the Malaria Immunology Group at ISGlobal. Her group aims at in-depth immune profiling of influenza-vaccinated subjects across diverse European and Indian populations to guide the development of next-generation vaccines. The group aims at understanding the antibody response to influenza antigens in the vaccine trials of European cohorts. Her group is also leading the work package -Partnership building, knowledge, technology transfer- aimed at coordinating technology transfer and standardisation to strengthening the partnership between European and Indian partners.
Elisa Sicuri is Assistant Research Professor at ISGlobal. Her specific task involves eliciting preferences for influenza vaccines and vaccinations with the aim of exploring a theoretical demand in Europe and India. To do so, a discrete choice experiment (DCE) will be performed in India among trial participants and among a sub-sample of a large general population cohort. In Europe, selected key questions will be asked to trial participants with the additional aim of eliciting potential trade-offs between influenza and COVID-19 vaccines. The same selected questions will be asked in India aiming for a pooled analysis.
This project has received funding from the European Union H2020 (grant no. 874866) and the Dept. of Biotechnology, Govt. of India (project no. BT/IN/EU-INF/16/AP/19-20/11746)